

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone DPI pwdr [A] mometasone MDI aerosol [A]	<p>Inhaled Corticosteroids</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of Asthma, I move that</p> <p>beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone MDI aerosol [A] mometasone DPI powder [A]</p> <p>are safe and efficacious for the treatment of their approved indications. Inhaled corticosteroids can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Johnson 2nd: Bowman</p>	October 19, 2016	NA	No	Passed unanimous

Bold = new this update
 [A] = Approved for Asthma, [C] = Approved for COPD
10/24/2016

**P&T Motion History
Asthma Controller / COPD Drugs**

<p>arformoterol [C] formoterol neb soln [C] formoterol DPI pwdr [A,C] indacaterol [C] olodaterol [C] salmeterol [A,C]</p>	<p>Long Acting Beta Agonists After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that arformoterol [C] formoterol nebulizer sol [C] formoterol pwdr [A,C] indacaterol [C] olodaterol [C] salmeterol [A,C] are safe and efficacious for the treatment of COPD and when used in the combination with inhaled corticosteroids for the treatment of asthma. Long Acting Beta Agonists can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated. Motion: Figueroa 2nd: Harvey</p>	<p>October 19, 2016</p>	<p>NA</p>	<p>No</p>	<p>Passed unanimous</p>
--	--	-----------------------------	-----------	-----------	-----------------------------

Bold = new this update

[A] = Approved for Asthma, [C] = Approved for COPD

10/24/2016

**P&T Motion History
Asthma Controller / COPD Drugs**

<p>montelukast [A] zafirlukast [A] zileuton [A]</p>	<p>Leukotriene Modifiers After considering the evidence of safety, efficacy and special populations for the treatment of asthma, I move that montelukast, zafirlukast, and zileuton are efficacious. Montelukast and zafirlukast may be associated with a lower incidence of hepatic toxicity than zileuton. Zileuton shall not be a preferred drug on the Washington Preferred drug list. Leukotriene modifiers can be subject to therapeutic interchange on the Washington Preferred Drug List for the indication of asthma.</p> <p>Motion: Klingel 2nd: Smith</p>	<p>October 19, 2016</p>	<p>NA</p>	<p>Yes Harvey Johnson</p>	<p>Passed unanimous</p>
---	--	-----------------------------	-----------	-----------------------------------	-----------------------------

**P&T Motion History
Asthma Controller / COPD Drugs**

<p><u>ICS/LABA</u> fluticasone propionate/ salmeterol DPI [A,C] fluticasone propionate/ salmeterol MDI [A] budesonide/formoterol [A,C] mometasone furoate/formoterol furoate [A] fluticasone furoate/vilanterol [A,C]</p>	<p>ICS/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that fluticasone propionate/salmeterol DPI and MDI [A,C], budesonide/ formoterol [A,C], fluticasone furoate/vilanterol [A, C] and mometasone furoate/formoterol [A] are safe and efficacious for the treatment of their approved indications. Long Acting Beta Agonist Combination with ICS products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated. Motion: Johnson 2nd: Bowman</p>	<p>October 19, 2016</p>	<p>NA</p>		<p>Passed unanimous</p>
<p><u>LAMA/LABA</u> indacaterol/glycopyrrolate [C] olodaterol/tiotropium [C] umeclidinium/vilanterol [C]</p>	<p>LAMA/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that indacaterol/glycopyrrolate [C] olodaterol/tiotropium [C] umeclidinium/vilanterol [C] are safe and efficacious for the treatment of their approved indications. Long Acting Beta Agonist Combination with LAMA products can be subject to therapeutic interchange in the Washington</p>				<p>Passed unanimous</p>

Bold = new this update

[A] = Approved for Asthma, [C] = Approved for COPD

10/24/2016

**P&T Motion History
Asthma Controller / COPD Drugs**

	preferred drug list if the preferred drug is approved for the condition being treated. Motion: Johnson 2 nd : Chew				
roflumilast [C]	Phosphodiesterase-4 Inhibitor After considering the evidence of safety, efficacy and special populations for the treatment of COPD, I move that roflumilast [C] is safe and efficacious for the treatment of COPD. Phosphodiesterase-4 inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Harvey 2 nd : Johnson	October 19, 2016	NA	Yes Harvey Chew	Passed unanimous
acclidinium [C] glycopyrrolate [C] tiotropium DPI pwdr [C] tiotropium SMI mist [A,C] umeclidinium [C]	Long-acting Muscarinic Antagonists (LAMA) After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that acclidinium [C], glycopyrrolate [C], tiotropium DPI powder [C], tiotropium SMI mist [A,C] and umeclidinium [C] are safe and efficacious for the treatment of their approved indications. LAMAs can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Chew 2 nd : Smith	October 19, 2016	NA		Passed unanimous

Bold = new this update

[A] = Approved for Asthma, [C] = Approved for COPD

10/24/2016

**P&T Motion History
Asthma Controller / COPD Drugs**

Bold = new this update

[A] = Approved for Asthma, [C] = Approved for COPD

10/24/2016